Yet, throughout the course of treatment, patients with multiple myeloma acquire and/or evolve previously undetected CH clones, particularly those with DNMT3A mutations, indicating that multiple myeloma treatment may accelerate the natural course of CH, the clinical significance of which will require further work. The gene discussed is DNMT3A; the disease is plasma cell myeloma.